Close Menu

IVF

Reproductive Medicine Associates of New Jersey is currently enrolling patients in a clinical validation trial of targeted next-generation sequencing-based preimplantation genetic testing to aid in the selection of embryos for transfer as part of in vitro fertilization.

This article was originally published on Jan. 29.
Microarrays are still a growing business for Illumina.

This article has been corrected to reflect that Illumina will seek Chinese FDA approval for a MiSeqDx-based NIPT assay, not a HiSeq2500-based assay, as previously reported.

Oxford Gene Technology this week launched a new microarray that can be used to screen embryos for chromosomal abnormalities prior to implantation during an in vitro fertilization cycle.

This story was originally posted on March 7

Illumina's acquisition of BlueGnome has provided a boost for its array business.

This story was originally posted on Oct. 24

Good Start Genetics has expanded the disorders it covers in its sequencing-based preconception carrier screening service to 23 after launching a more limited panel in April.

This article has been updated from a version posted Sept. 19 to include comments from Illumina officials.

Using arrays to screen embryos during an in vitro fertilization cycle can improve pregnancy rates, according to a new study.

Pages

23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.

China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.

In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.

NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.